SG Americas Securities
APGE icon

SG Americas Securities’s Apogee Therapeutics APGE Stock Holding History

SG Americas Securities’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21M Buy
31,698
+21,491
+211% +$1.94M ﹤0.01% 1165
2026
Q1 		$859K Sell
10,207
-63,055
-86% -$4.58M ﹤0.01% 1865
2025
Q4 		$5.53M Sell
73,262
-60,964
-45% -$3.84M 0.01% 1047
2025
Q3 		$5.33M Buy
+134,226
New +$5.13M 0.02% 489
2025
Q1 		– Sell
-9,890
Closed -$448K – 3457
2024
Q4 		$448K Buy
9,890
+1,796
+22% +$91.6K ﹤0.01% 1430
2024
Q3 		$475K Buy
+8,094
New +$388K ﹤0.01% 1731
2024
Q2 		– Sell
-2,317
Closed -$154K – 2835
2024
Q1 		$154K Sell
2,317
-4,290
-65% -$187K ﹤0.01% 2176
2023
Q4 		$185K Buy
6,607
+1,676
+34% +$33.6K ﹤0.01% 2237
2023
Q3 		$105K Buy
+4,931
New +$109K ﹤0.01% 2763

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

SG Americas Securities's APGE Position: Q2 2026 in Review

SG Americas Securities increased its Apogee Therapeutics (APGE) stake by 211% in Q2 2026, buying an estimated $1.94M and bringing the position to 31,698 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

SG Americas Securities first reported a position in APGE in Q3 2023 and has held it in 9 quarters since. The position peaked at $5.53M in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • SG Americas Securities held 31,698 shares of Apogee Therapeutics worth $4.21M as of Q2 2026.
  • SG Americas Securities bought 21,491 Apogee Therapeutics shares in Q2 2026, an estimated $1.94M.
  • Apogee Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1165 holding.
  • SG Americas Securities first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • SG Americas Securities's Apogee Therapeutics position peaked at $5.53M in Q4 2025.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.